The clinicopathological parameters and prognostic significance of HER2 expression in gastric cancer patients: a meta-analysis of literature
Tóm tắt
Từ khóa
Tài liệu tham khảo
Akiyama T, SUDo C, Ogawara H, et al. The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science. 1986;232(4758):1644–6.
Casalini P, Iorio MV, Galmozzi E, et al. Role of HER receptors family in development and differentiation. J Cell Physiol. 2004;200(3):343–50.
Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol. 2008;19(9):1523–9.
Luo H-Q, Han L, Jiang Y. Meta-analysis of six randomized control trials of chemotherapy plus anti-HER monoclonal antibody for advanced gastric and gastroesophageal cancer. Asian Pac J Cancer Prev. 2014;15(13):5343–8.
Ciliberto D, Staropoli N, Caglioti F, et al. A systematic review and meta-analysis of randomized trials on the role of targeted therapy in the management of advanced gastric cancer: evidence does not translate? Cancer Biol Ther. 2015;16(8):1148–59.
Bang Y-J, Cutsem EV, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–97.
Kurokawa Y, Sugimoto N, Miwa H, et al. Phase II study of trastuzumab in combination with S-1 plus cisplatin in HER2-positive gastric cancer (HERBIS-1). Br J Cancer. 2014;110(5):1163–8.
Mitsui Y, Sato Y, Miyamoto H, et al. Trastuzumab in combination with docetaxel/cisplatin/S-1 (DCS) for patients with HER2-positive metastatic gastric cancer: feasibility and preliminary efficacy. Cancer Chemother Pharmacol. 2015;76(2):375–82.
Yi JH, Kang JH, Hwang IG, et al. A retrospective analysis for patients with HER2 positive gastric cancer who were treated with trastuzumab-based chemotherapy: in the perspectives of ethnicity and histology. Cancer Res Treat. 2015;48(2):553–60.
Kim YS, Sym SJ, Baek MY, et al. Low-dose capecitabine plus trastuzumab as first-line treatment in patients 75 years of age or older with HER2-positive advanced gastric cancer: a pilot study. Cancer Chemother Pharmacol. 2015;76:1267–72.
Yan SY, Hu Y, Fan JG, et al. Clinicopathologic significance of HER-2/neu protein expression and gene amplification in gastric carcinoma. World J Gastroenterol. 2011;17(11):1501–6.
Aizawa M, Nagatsuma AK, Kitada K, et al. Evaluation of HER2-based biology in 1,006 cases of gastric cancer in a Japanese population. Gastric Cancer. 2014;17(1):34–42.
Kurokawa Y, Matsuura N, Kimura Y, et al. Multicenter large-scale study of prognostic impact of HER2 expression in patients with resectable gastric cancer. Gastric Cancer. 2015;18(4):691–7.
Matsusaka S, Nashimoto A, Nishikawa K, et al. Clinicopathological factors associated with HER2 status in gastric cancer: results from a prospective multicenter observational cohort study in a Japanese population (JFMC44-1101). Gastric Cancer. 2015;19(3):1026.
Tang D, Liu CY, Shen D, et al. Assessment and prognostic analysis of EGFR, HER2, and HER3 protein expression in surgically resected gastric adenocarcinomas. Onco Targets Ther. 2015;8:7–14.
Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–5.
Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.
Dursun A, Poyraz A, Celik B, et al. Expression of c-erbB-2 oncoprotein in gastric carcinoma: correlation with histopathologic characteristics and analysis of Ki-67. Pathol Oncol Res. 1999;5(2):104–6.
Song HS, Do YR, Kim IH, et al. Prognostic significance of immunohistochemical expression of EGFR and C-erbB-2 oncoprotein in curatively resected gastric cancer. Cancer Res Treat. 2004;36(4):240–45.
Tanner M, Hollmen M, Junttila TT, et al. Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol. 2005;16(2):273–8.
Park DI, Yun JW, Park JH, et al. HER-2/neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci. 2006;51(8):1371–9.
Ismail HM, Moneer M, El-baradie M, et al. Clinicopathologic and prognostic significance of overexpression of Her-2/neu and p53 oncoproteins in gastric carcinoma using tissue microarray. J Egypt Natl Canc Inst. 2007;19(2):147–57.
Kim MA, Jung EJ, Lee HS, et al. Evaluation of HER-2 gene status in gastric carcinoma using immunohistochemistry, fluorescence in situ hybridization, and real-time quantitative polymerase chain reaction. Hum Pathol. 2007;38(9):1386–93.
Zhang XL, Yang YS, Xu DP, et al. Comparative study on overexpression of HER2/neu and HER3 in gastric cancer. World J Surg. 2009;33(10):2112–8.
Cidon EU, Centeno RG, Lagarto EG, et al. HER-2 evaluation in a specific gastric cancer population with the highest rate of mortality in Spain. J Oncol. 2011;2011:391564.
Ansari J, Chehrei A, Amini M, et al. The prognostic significance of Her2-Neu overexpression in gastric carcinomas. Iran J Cancer Prev. 2011;4:170–6.
Kim KC, Koh YW, Chang HM, et al. Evaluation of HER2 protein expression in gastric carcinomas: comparative analysis of 1,414 cases of whole-tissue sections and 595 cases of tissue microarrays. Ann Surg Oncol. 2011;18(10):2833–40.
Chan DS, Campbell F, Edwards P, et al. Relative prognostic value of human epidermal growth factor receptor 2 (HER2) expression in operable oesophagogastric cancer. ISRN Surg. 2012;2012:804891.
Chaturvedi R, Singh AB. HER2 as a therapeutic target in the gastric cancer: is it sufficient? Indian J Gastroenterol. 2012;31(3):103–5.
Cho J, Jeong J, Sung J, et al. A large cohort of consecutive patients confirmed frequent HER2 positivity in gastric carcinomas with advanced stages. Ann Surg Oncol. 2012;20(S3):477–84.
Dang HZ, Yu Y, Jiao SC. Prognosis of HER2 over-expressing gastric cancer patients with liver metastasis. World J Gastroenterol. 2012;18(19):2402–7.
Janjigian YY, Werner D, Pauligk C, et al. Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis. Ann Oncol. 2012;23:2656–62.
Kunz PL, Mojtahed A, Fisher GA. HER2 expression in gastric and gastroesophageal junction adenocarcinoma in a US population: clinicopathologic analysis with proposed approach to HER2 assessment. Appl Immunohistochem Mol Morphol. 2012;20:13–24.
Zhou F, Li N, Jiang W, et al. Prognosis significance of HER-2/neu overexpression/amplification in Chinese patients with curatively resected gastric cancer after the ToGA clinical trial. World J Surg Oncol. 2012;10(1):274.
Aoyama T, Yoshikawa T, Miyagi Y, et al. Human epidermal growth factor receptor 2 (Her-2) and S-1 adjuvant chemotherapy in stage 2/3 gastric cancer patients who underwent D2 gastrectomy. Surg Today. 2013;43(12):1390–7.
Bayrak M, Olmez OF, Kurt E, et al. Prognostic significance of c-erbB2 overexpression in patients with metastatic gastric cancer. Clin Transl Oncol. 2013;15(4):307–12.
Fan XS, Chen JY, Li CF, et al. Differences in HER2 over-expression between proximal and distal gastric cancers in the Chinese population. World J Gastroenterol. 2013;19(21):3316–23.
Gasljevic G, Lamovec J, Contreras JA, et al. HER2 in gastric cancer: an immunohistochemical study on tissue microarrays and the corresponding whole-tissue sections with a supplemental fish study. Pathol Oncol Res. 2013;19(4):855–65.
He C, Bian XY, Ni XZ, et al. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer. World J Gastroenterol. 2013;19(14):2171–8.
Shan L, Ying J, Lu N. HER2 expression and relevant clinicopathological features in gastric and gastroesophageal junction adenocarcinoma in a Chinese population. Diagn Pathol. 2013;8:76–83.
Geng Y, Chen X, Qiu J, et al. Human epidermal growth factor receptor-2 expression in primary and metastatic gastric cancer. Int J Clin Oncol. 2014;19(2):303–11.
Qiu M, Zhou Y, Zhang X, et al. Lauren classification combined with HER2 status is a better prognostic factor in Chinese gastric cancer patients. BMC Cancer. 2014;14:823–31.
Son HS, Shin YM, Park KK, et al. Correlation between HER2 overexpression and clinicopathological characteristics in gastric cancer patients who have undergone curative resection. J Gastric Cancer. 2014;14(3):180–6.
Yana Y, Lub L, Liub C, et al. HER2/neu over-expression predicts poor outcome in early gastric cancer without lymph node metastasis. Clin Res Hepatol Gastroenterol. 2014;39:121–26.
Gu J, Zheng L, Zhang L, et al. TFF3 and HER2 expression and their correlation with survival in gastric cancer. Tumour Biol. 2015;36(4):3001–7.
He XX, Ding L, Lin Y, et al. Protein expression of HER2, 3, 4 in gastric cancer: correlation with clinical features and survival. J Clin Pathol. 2015;68:374–80.
Laboissiere RS, Buzelin MA, Balabram D, et al. Association between HER2 status in gastric cancer and clinicopathological features: a retrospective study using whole-tissue sections. BMC Gastroenterol. 2015;15:157.
Li HE, Wang X, Tang Z, et al. A concordant expression pattern of fatty acid synthase and membranous human epidermal growth factor receptor 2 exists in gastric cancer and is associated with a poor prognosis in gastric adenocarcinoma patients. Oncol Lett. 2015;10(4):2107–17.
Madani S-H, Rahmati A, Payandeh M, et al. Survey of Her2-neu expression and its correlation with histology of gastric carcinoma and gastroesophageal junction adenocarcinoma. Asian Pac J Cancer Prev. 2015;16(17):7755–58.
Matsumoto T, Sasako M, Mizusawa J, et al. HER2 expression in locally advanced gastric cancer with extensive lymph node (bulky N2 or paraaortic) metastasis (JCOG1005-A trial). Gastric Cancer. 2015;18(3):467–75.
Rajagopal I, Niveditha SR, Sahadev R, et al. HER 2 expression in gastric and gastro-esophageal junction (GEJ) adenocarcinomas. J Clin Diagn Res. 2015;9(3):EC06–10.
Wu H, Cai Z, Lu G, et al. Impact of c-erbB-2 protein on 5-year survival rate of gastric cancer patients after surgery: a cohort study and meta-analysis. Tumori. 2015;0. PMID:26549693. doi: 10.5301/tj.5000444 .
Terashima M, Kitada K, Ochiai A, et al. Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer. Clin Cancer Res. 2012;18(21):5992–6000.
Hofmann M, Stoss O, Shi D, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology. 2008;52(7):797–805.
McCubrey JA, Steelman LS, Chappell WH, et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta. 2007;1773(8):1263–84.
Junttila TT, Akita RW, Parsons K, et al. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell. 2009;15(15):429–40.
Konecny GE, Untch M, Bauerfeind I, et al. Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients. Clin Cancer Res. 2004;10:1706–16.